baber/WOPTO huggingface dataset:
Patent FI-952318-A0 (FI)
Inventor: PRYOR DENNIS MALCOLM
IPC: H03K/
Filed: 1995-05-12
Abstract: PCT No. PCT/GB93/02312 Sec. 371 Date Aug. 17, 1995 Sec. 102(e) Date Aug. 17, 1995 PCT Filed Nov. 10, 1993 PCT Pub. No. WO94/11948 PCT Pub. Date May 26, 1994A switching arrangement that can be connected in a communications channel that comprises a pair of lines between sets of terminal equipment, which comprises: (i) a series switch (1,2) for connection in each of the lines; (ii) a shunt switch for connection between the lines; and (iii) a control circuit (5) that can actuate the series switches (1,2) and can actuate the shunt switch on receipt of a signal sent along the channel: wherein the control circuit (5) can actuate the shunt switch and the series switches (1,2) on receipt of one or more signals but the shunt switch will remain closed over a different time period than that during which the series switches remain open, in order to allow different tests to be performed on the channel, and wherein one or more of the switches comprises a solid state switch.
Patent FI-962143-A0 (FI)
Inventor: ARDITI MARCEL
IPC: A61K49/00
Filed: 1996-05-21
Abstract: Echographic imaging (such as used for medical diagnosis) uses the injection of specific contrast agents in the body, or more generally in the region to be imaged. Different frequency dependent echographic behavior of the ultrasound contrast agents containing microbubbles as compared to echographic behavior of tissue without contrast agents is exploited by providing separated spectral echo responses and then combining them in ways to enhance image contrast. These imaging principles exploit certain physical "signatures" of the contrast agent responses, allowing increased contrast with respect to tissue background. This contrast enhancement is much larger than what is determined from direct echo amplitude monitoring.
Patent FI-972378-A0 (FI)
Inventor: DERLETH HELMUT
IPC: C02F1/70
Filed: 1997-06-05
Abstract: The invention concerns a method of catalytically treating waste water which contains halogen-organic and other organic and inorganic compounds. The waste water is treated in the presence of hydrogen on a supported noble metal catalyst, a zirconium oxide-supported palladium catalyst being used according to the invention.
Patent FI-972413-A0 (FI)
Inventor: GOLZ KARIN
IPC: A61Q17/04
Filed: 1997-06-06
Abstract: PCT No. PCT/DE95/01801 Sec. 371 Date May 9, 1997 Sec. 102(e) Date May 9, 1997 PCT Filed Dec. 6, 1995 PCT Pub. No. WO96/17588 PCT Pub. Date Jun. 13, 1996The invention involves a cosmetic preparation containing kaolin which may be employed as a mask, lotion, gel or cream with a non-sticky, non-plasticized consistency and with a content of white kaolin with a high proportion of kaolinite and spherical inorganic particles of a particle size of less than 5  mu m, with a proportion of spherical particles in the kaolin mixture of 0.5 to 10% by weight as well as a cosmetic skin care composition, in which the proportion of the kaolin/spherical particle mixture falls within the range of over 2 to 65% by weight of the composition as a whole. The viscosity of the composition with the proportion of kaolin/spherical particles is around 2000 to over 15,000 cps higher than a similar composition with kaolin only and without spherical particles, with the difference in viscosity increasing with the proportion of kaolin/spherical particles. The new, pleasantly soft preparation with an inhibitive effect with regard to inflammation permits high kaolin contents to be used to especially good effect in masks and gels.
Patent FI-973807-A0 (FI)
Inventor: CHRISTIANSEN JAN
IPC: B24B19/16
Filed: 1997-09-26
Abstract: The invention is a grinding apparatus for grinding tips of welding electrodes. An apparatus for grinding welding electrodes in accordance with the invention includes a drive motor for rotating a grinding disc and an electrode holder for fixing a welding electrode at an angle in relation to the grinding disc, the holder having a part which is displaceable vertically parallel to a plane of the grinding disc on a guide including first and second mutually displaced receivers for the electrode holder, the first receiver being positioned adjacent a scale provided on an outside of a housing which is used to set an angle at which a point of the electrode is to be ground with a radius of the scale being equal to a radius of the grinding disc and the second receiver fixing the electrode holder, which holds an electrode held therein having an end at which a point is to be ground by the grinding disc, parallel to the plane of the grinding disc with the point of the electrode engaging part of a periphery of the grinding disc with a vertical distance between the receivers being equal to a distance between the scale and the grinding disc.
Patent IL-69383-A0 (IL)
Title: Neutral sodium fluoride gel compositions
IPC: A61K8/21
Filed: 1983-08-01
Abstract: A neutral topical sodium fluoride gel is disclosed which comprises a thickened aqueous solution of sodium fluoride buffered to maintain a pH of from about 5 to 9.
Patent IL-71634-A0 (IL)
Title: Hybrid dna synthesis of mature human insulin-like growth factors
IPC: C12P21/02
Filed: 1984-04-25
Abstract: Prodn. of human insulin-like growth factor (IGF) comprises growing host cells contg. a structural gene which comprises a functional DNA construct of the gene encoding IGF joined in proper reading frame with secretory leader and processing signal sequences recognised by the host, and isolating secreted human IGF. The structural gene is downstream from and under transcriptional regulatory control of a transcriptional initiation region in a vector compatible with the host. The host is pref. a yeast. A DNA construct comprising a coding sequence for human IGF under transcriptional regulation of regulatory signals utilised by yeast is new. Also claimed is a construct contg. the IGF gene for expression in a cultured cellular host. Nucleotide sequences are defined with corresp. aminoacid sequence.
Patent IL-76215-A0 (IL)
Title: Benzodisultams,their preparation and their use as herbicides
IPC: A01N/
Filed: 1985-08-27
Abstract: The invention relates to new benzodisultams of the general formula (I)    <IMAGE>  (I)  in which R1 represents an optionally substituted radical from the series comprising alkyl, alkenyl, alkinyl, cycloalkyl, cycloalkylalkyl, aralkyl and aryl, R2 represents hydrogen or an optionally substituted radical from the series comprising alkyl, alkenyl, alkinyl and aralkyl, and R3 represents an optionally substituted and/or optionally fused six-membered aromatic heterocyclic radical which contains at least one nitrogen atom, a process for their preparation and their use as herbicides.
Patent IL-77166-A0 (IL)
Title: Non-reverting salmonella live vaccines
IPC: A61K39/00
Filed: 1985-11-27
Abstract: Live vaccines are provided and methods for preparing the live vaccines for protection of a host from a pathogenic microorganism. The vaccines are prepared by introducing at least one modification in a gene involved in at least one, normally at least two, biosynthetic pathways, involving the production of products which are unlikely to be found in the disease susceptible host. The modification results in a gene change which cannot be repaired by a single step e.g. polynucleotide deletions and inversions. Where the aro gene suffers such a change, the resultant auxotrophic mutants require aromatic amino acids, p-aminobenzoic acid and 2, 3-dihydroxybenzoic acid or a highly concentrated source of absorbable iron. The auxotrophic mutations have substantially reduced or nonexistent virulence, while retaining the desired immunogenicity to initiate the immunogenic response. Various techniques can be employed for providing the desired change. Salmonella typhimurium strain SL1479 was deposited at the ATCC on September 7, 1982 and given ATGG Accession No. 39183; Salmonella dublin strain SL1438 was deposited on September 7, 1982 at the ATCC and given ATCC Accession No. 39184. Salmonella typhi strain 531Ty was deposited at the ATCC on November 21, 1984, and granted ATCC Accession No. 39926. This application is a continuation-in-part of U.S. Serial No. 675,381, filed November 27, 1984 which is a continuation-in-part of U.S. Serial No. 415,291, filed September 7, 1982 now U.S. Patent No. 4,550,081, issued October 29, 1985, which is a continuation-in-part of U.S. Serial No. 151,002, filed May 19, 1980, now abandoned, which disclosures are incorporated herein by reference.
Patent IL-84928-A0 (IL)
Title: Compositions and methods for the synthesis and assay of enkephalinase
IPC: G01N33/573
Filed: 1987-12-23
Abstract: An enkephalinase assay is provided in which enkephalinase activity is measured by following the hydrolysis of dansylated peptides e.g. dansyl-Gly-Trp-Gly and dansyl-Gly-Tyr-Gly, by fluorescence measurements.
Patent IL-92856-A0 (IL)
Title: Process for the in vivo recombination of partially homologous dna sequences
IPC: C12N15/10
Filed: 1989-12-22
Abstract: The present invention relates to a process of recombination in vivo of partially homologous DNA sequences having up to 30% of base mismatches. According to its essential characteristic, said sequences are placed together in cells or an organism of which the enzymatic mismatch repair system is defective or has been transitorily inactivated by saturation for the time to obtain recombination between said DNA sequences or in using mutants which increase the intergeneric recombination.
Patent IL-98056-A0 (IL)
Title: Neuroprotective indolone and related derivatives
IPC: A61K31/404
Filed: 1991-05-03
Abstract: PCT No. PCT/US91/01470 Sec. 371 Date Nov. 6, 1992 Sec. 102(e) Date Nov. 6, 1992 PCT Filed Mar. 4, 1991 PCT Pub. No. WO91/17156 PCT Pub. Date Nov. 14, 1991.5-(1-Hydroxy-2-piperidinopropyl)-2(1H,3H)-indolone derivatives and analogs; pharmaceutical compositions thereof; methods of treating CNS disorders therewith; and intermediates useful in the preparation of said compounds.
Patent IL-99062-A0 (IL)
Title: Gonadoliberin antagonists
IPC: C07K7/06
Filed: 1991-08-02
Abstract: Peptides of the formula <IMAGE> in which X is alkanoyl, A is optionally substituted D-Na(2), D-Phe or D-Trp, B is optionally substituted D-Phe, C is D-Pal(3) or optionally substituted D-Phe or D-Trp, and D is Tyr or His, E is D-Ser(R<1>), F is Leu, Trp or Phe, G is L-Ser(R<1>), H is Gly-NH2, D-Ala-NH2 or azagly-NH2 and R<1> is a glycosyl radical, have inhibitory effects on the formation of the gonadotropins lutropin and follitropin and thus also on the synthesis of testosterone and oestrogen. A process for the preparation of these peptides is described.
Patent IL-99995-A0 (IL)
Title: Erythromycin derivatives,their preparation process,the new intermediates obtained and their use as medicaments
IPC: C07H17/00
Filed: 1991-11-07
Abstract: The invention relates to the compounds (I): <IMAGE>  in which,   - either X and X' form C=O or C=NOR with R=H, heterocycle, alkyl, alkenyl, alkynyl, optionally substituted,   or X represents a radical <IMAGE> R<a>, Rb representing H or hydrocarbon radical or forming a heterocycle with N or a 9-N, 11-O ring with A   and X' = H,   - Y and Y' have the same meaning as X and X',   - B = H, OR4, R4 = H or forms a carbonate or a carbamate with A,   - A forms a double bond with C, or   - A = OR'4, R'4 = H or forms a carbonate with B <IMAGE> R2 = alk or CONH2, CONHCOR11 or CONHSO2R11, R11 = hydrocarbon up to 18 C,   R3 = H, alkyl <IMAGE>   Z = H or carboxylic acid residue, and their salts, their preparation and their application as medicaments.
Patent AU-PP572498-A0 (AU)
Title: Moveable element lock and key
IPC: E05B19/12
Filed: 1998-09-04
Abstract: A key is provided with an actuator. The key also has operation structure and interaction structure. When the key is inserted into a lock, a force is applied to the operation structure and the position of the interaction structure is altered. The movement of the interaction structure is used in the locking and/or un-locking mechanism of the lock. A key handle and lock are also provided which incorporate such a mechanism.
Patent FI-20001425-A0 (FI)
Inventor: HAERMAE ESA
IPC: H04M1/72427
Filed: 2000-06-15
Abstract: A method and arrangements are provided for distributing a recreational application within a group of terminal arrangements (1101, 1102). The group comprises at least two terminal arrangements and each terminal arrangement comprises a terminal of a cellular radio system. Within the method, there is transmitted from a first terminal arrangement to a second terminal arrangement a proposal (104, 204, 704) for setting up a session of utilizing a recreational application. Only after the second terminal arrangement has received said proposal, one used (107, 108, 207, 208, 308, 408, 409, 508, 509, 510, 607, 608, 609, 610, 611, 707, 710, 711) the communicational capabilities of at least one of the first and second terminal arrangements to establish a state where both the first terminal arrangement and the second terminal arrangement possess enough software components (1103, 1104, 1105, 1106, 1205) for setting up a common, shared session of utilizing said recreational application.
Patent FI-20060832-A0 (FI)
Inventor: RIEKKINEN TOMMI
IPC: H01G/
Filed: 2006-09-18
Abstract: A fabrication method for parallel-plate structures and a parallel-plate structure arrangement, wherein the structures have a middle layer, grown on a substrate and disposed between top and bottom electrode layers, wherein the middle layer and the top and bottom electrode layers are deposited on a bottom substrate, and wherein the middle layer is grown first and the top and bottom electrodes are essentially deposited afterwards.
Patent IL-106446-A0 (IL)
Title: Curable aqueous composition and its use as fiberglass nonwoven binder
IPC: D06M13/322
Filed: 1993-07-22
Abstract: This invention relates to a formaldehyde-free curable aqueous composition containing a polyacid, a polyol and an optional phosphorous-containing accelerator. The composition may be used as a binder for heat resistant nonwovens such as nonwovens composed of fiberglass.
Patent IL-112261-A0 (IL)
Title: Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
IPC: A61K48/00
Filed: 1995-01-05
Abstract: The present invention concerns an oligonucleotide compound, which comprises a ribozyme targeted to the GUA target site at nucleotide 5849 of the HIV-1 SF-2 isolate or a corresponding target site of other HIV-1 isolates. The invention also relates to transfer vectors comprised of RNA or DNA or a combination thereof which on transcription give rise to said compound, to cells comprising a nucleotide sequence which is, or on transcription gives rise to, said compound and to pharmaceutical compositions containing said compound or said transfer vector. <IMAGE>
Patent IL-113869-A0 (IL)
Title: Acylated enol derivatives as prodrugs of elastase inhibitors
IPC: A61K31/535
Filed: 1995-05-26
Abstract: This invention relates to acylated enol derivatives of known elastase inhibitors. These compounds are useful in the treatment of various inflammatory diseases, including cystic fibrosis and emphysema or as prodrugs of compounds which are useful in the treatment of said diseases.
Patent IL-115682-A0 (IL)
Title: Cryptdin peptides methods for the preparation thereof and pharmaceutical compostions containing the same
IPC: C07K14/46
Filed: 1995-10-19
Abstract: The present invention provides substantially purified cryptdin peptides having a consensus amino acid sequence:wherein X1 is 3 to 9 amino acids; X2 is one amino acid, preferably Y, H or R; X3 is 2 or 3 amino acids; X4 is three amino acids; X5 is five amino acids; X6 is 6 to 10 amino acids; and X7 is 0 to 9 amino acids. The invention also provides a substantially purified mouse cryptdin having a consensus amino acid sequence:wherein X1 is 3 or 4 amino acids, preferably LRD, LSKK (SEQ ID NO: 1) or LRG; X2 is 1 amino acid, preferably V, L or I; X3 is 3 amino acids, preferably KGH or *RG, where * is S, T, K, I or A; X4 is 2 amino acids, preferably GR, RR or RG; X5 is 3 amino acids, preferably RMN, RVR, RVF HMN or HIN; X6 is 6 to 9 amino acids, preferably GIRFLY (SEQ ID NO: 2) or RNLFLTFVF (SEO ID NO: 3), RRGHLMYTL (SEQ ID NO: 4) or RKGHL*YT* (SEQ ID NO: 5), where * independently is L or M; and X7 is 0 to 3 amino acids, preferably R, S or PRR. The invention also provides cryptdin analogs, which are devoid of one or more amino acids N-terminal to the first cysteine. In addition, the invention provides nucleic acid molecules encoding cryptdin peptides. The invention further provides methods for detecting inflammatory pathologies in a subject and for treating an inflammatory pathology in a subject by administering a pharmaceutical composition containing a cryptdin peptide.
Patent IL-121163-A0 (IL)
Title: Irradiating device
IPC: H05B41/34
Filed: 1997-06-25
Abstract: An irradiating system comprising an irradiating device is disclosed. An input of the irradiating device is connected to a capacitive energy storage device via a switching means, and a control unit is connected to the switching means and is operable to actuate the switching means. Means for inputting to the control unit a variable demand value of output energy (ED) representative of a user requirement of energy to be discharged as a pulse of radiant energy from the irradiating device is also disclosed, as is means for inputting to the control unit a variable demand value of output pulse length (tD) corresponding to a user requirement of pulse length of the pulse of radiant energy. The control unit is operable and having an estimated voltage value (VE) representative of a voltage to which the energy storage device is required to be charged to enable the irradiating device to receive sufficient electrical current for the pulse of radiant energy to have actual values of output energy and output pulse length (EO, tO) corresponding substantially to the demand value of output energy (ED) and the demand value of output pulse length (tD) respectively. A charging circuit is provided to charge the storage device to a supply voltage VS corresponding to the estimated voltage value as is trigger means, to close the switching means to initiate a supply of current (i) to the input of the irradiating device. The control unit is operable to open the switching means to terminate the resulting pulse of radiant energy such that the supply of current to the input of the irradiating device is terminated before complete discharge of the energy storage device. <IMAGE>
Patent IL-127733-A0 (IL)
Title: Chelating agents and their metal chelates for treating free radical induced conditions
IPC: A61K45/00
Filed: 1997-06-24
Abstract: The invention relates to the use of certain chelating agents and their metal chelates and to the use of certain manganese containing compounds, in particular manganese chelates, in the manufacture of a therapeutic agent for use in reducing the cardiotoxicity of an antitumor agent. Such compounds are particularly effective in reducing the side-effects of anthracycline drugs and/or paclitaxel.
Patent IL-134297-A0 (IL)
Title: Coating compounds based on silanes containing epoxide groups
IPC: C09D183/06
Filed: 1998-08-17
Abstract: The present invention provides a coating composition which comprises at least one silicon compound (A) which has at least one radical which is bonded directly to Si, is not able to be separated hydrolytically and contains an epoxy group, a particulate material (B) which is selected from among oxides, oxide hydrates, nitrides and carbides of Si, Al and B and of transition metals and has a particle size within the range 1 to 100 nm, an Si, Ti, Zr, B, Sn or V compound (C) and at least one hydrolysable Ti, Zr or Al compound (D), which comprises the following ratio1.0 mol of the silicon compound (A),0.27 to 0.49 mol of the particulate material (B),0.36 to 0.90 mol of the compound (C) and0.14 to 0.22 mol of the compound (D).
Patent IL-136587-A0 (IL)
Title: Fast drying ink jet ink compositions for capping ink jet printer nozzles
IPC: C09D11/00
Filed: 2000-06-05
Abstract: Methods and apparatus are provided for preventing clogging in impulse ink jet printers. It has been found in accordance wit the invention that ink clogging during quiescent periods can be prevented by providing an ink that has the property of forming a barrier of higher viscosity ink where the ink contacts the ambient air. As a result, the viscous barrier shields the remaining ink from the effects of air exposure during the quiescent period. Thereafter, the barrier is removed by a series of sub-pulses that re-homogenize the viscosity barrier and clear the nozzle.  <IMAGE>
Patent IL-156545-A0 (IL)
Title: Back-up battery for a cellular telephone
IPC: H01M50/209
Filed: 2001-12-21
Abstract: The present invention relates to a back-up battery for an electronic device with a rechargeable battery, which electronic device is provided with a contact for connecting a battery charger and which back-up battery consists of one or more battery cells. According to the invention the terminals on the back-up battery are connected to a contact adapted to the contact for the battery charger on the electronic device, with the result that when it is connected to the electronic device's battery charger contact the back-up battery will charge the electronic device's rechargeable battery, thereby providing increased service life for the electronic device. <IMAGE>
Patent IL-157497-A0 (IL)
Title: Aerated frozen product
IPC: A23G9/04
Filed: 2002-03-04
Abstract: An aerated frozen product comprising less than 8% fat by weight and characterized in that the aerated frozen product comprises fat platelets, and after it has been melted and cooled, comprises fat platelets and spherical fat globules at a platelet to sphere ratio of greater than 0.02.
Patent IL-158370-A0 (IL)
Title: Method for multiple access and transmission in a point-to multipoint system on an electrical network
IPC: H04L5/02
Filed: 2002-04-17
Abstract: The invention relates to a plurality of user equipment (A, B, ...X) and to a piece of headend equipment (1) which are connected via the electrical network (2) by means of an ascending channel and a descending channel. The inventive method essentially offers the following: access to multiple pieces of user equipment (A, B,..X) via the ascending channel and the sending of multiple information frames sent by the headend equipment (1) via the descending channel, in a simultaneous manner using OFDMA/TDMA/CDMA multiplexing; a criterion that is used to dynamically assign each carrier in such a way as to maximise the transmission capacity of both the ascending channel and the descending channel; a quality of service that can be adapted according to the type of information and the user requesting the transmission; and a dynamic allocation of the bandwidth by means of a calculation and the constant monitoring of the signal/noise ratios. <IMAGE>
Patent IL-159996-A0 (IL)
Title: Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
IPC: C07C405/00
Filed: 2002-07-22
Abstract: A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP 4  agonist as an active ingredient. An EP 4  agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).